Tag: xenografts

Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes

Read the Full Video Transcript Andrea Miyahira: Welcome. I’m Andrea Miyahira and I’m the senior director of Global Research and Scientific Communications at the Prostate Cancer Foundation. Today I’m joined by Dr. Gavin Ha, an assistant professor at Fred Hutchinson Cancer Center and the PCF 2019 Young Investigator. Dr. Ha’s…

Continue Reading Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes

Human bone marrow-derived mesenchymal stem overexpressing microRNA-124-3p inhibit DLBCL progression by downregulating the NFATc1/cMYC pathway | Stem Cell Research & Therapy

Microarray-based expression analysis and GEO database analysis The DLBCL-related miRNA expression profiles of GSE29493 and GSE40239 were retrieved from the Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo/). MiR-124’s pan cancer analysis is conducted through online websites (www.picb.ac.cn/dbDEMC/). Bioinformatics predicted NFATc1 as the target of miR-124-3p The miRbase (www.mirbase.org/), miRDB (mirdb.org), and…

Continue Reading Human bone marrow-derived mesenchymal stem overexpressing microRNA-124-3p inhibit DLBCL progression by downregulating the NFATc1/cMYC pathway | Stem Cell Research & Therapy

Bioinformatics Tool for Tracking Tumor-Immune Interactions Could Be Useful for Guiding Therapy

NEW YORK – A bioinformatics tool developed by researchers at MD Anderson Cancer Center may help researchers find interactions between tumor-associated genes and immune checkpoints that are predictive of immunotherapy response. Immune checkpoints that are associated with tumor-related processes and immune phenotypes are known to be drivers of immune evasion…

Continue Reading Bioinformatics Tool for Tracking Tumor-Immune Interactions Could Be Useful for Guiding Therapy

IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma

Differential expression analysis We downloaded GSE125361 (n = 48) microarray data from the Gene Expression Omnibus (GEO) database, which included 45 myeloma samples and 3 controls, for expression analysis of IL5RA in cancer16. Additionally, we analyzed the expression of IL5RA in smoldering myeloma (SMM) patients who progressed to active MM (n = 10) and…

Continue Reading IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma

Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer

Molecular profiling reveals common changes in matched pairs of HNSCC primary tumor and metastasis-derived cell lines Identification of both genetic and functional differences between primary and metastatic variants of HNSCC would be enabled by in vitro models derived independently from these sites from the same patient. Unfortunately, HNSCC tumor cells…

Continue Reading Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer

Mice Model Market Research Report 2023: A $2.7 Billion

Dublin, May 12, 2023 (GLOBE NEWSWIRE) — The “Mice Model Market by Model Types & Services (Inbred Mice, Genetically Engineered Mice), Technology (Microinjection, Nuclear Transfer, CRISPR/CAS9), Application (PDx Models, Drug Discovery), End User (Pharma, Biotech, CROs, CDMOs) – Global Forecast to 2028” report has been added to ResearchAndMarkets.com‘s offering. The…

Continue Reading Mice Model Market Research Report 2023: A $2.7 Billion

Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation | Clinical Epigenetics

5-Azacytidine pretreatment resensitizes cisplatin-resistant DLBCL cell lines to cisplatin to varying degrees A platinum-based anti-neoplastic agent is an essential component of salvage regimens for aggressive lymphomas, for example, rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) for relapsed/refractory DLBCL and Hodgkin lymphoma [21]. As a single agent in humans, cisplatin is administered…

Continue Reading Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation | Clinical Epigenetics

Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia

doi: 10.1158/2643-3230.BCD-22-0167. Online ahead of print. Andriana G Kotini #  1   2   3   4 , Saul Carcamo #  1   5 , Nataly Cruz-Rodriguez #  1   2   3   4 , Malgorzata Olszewska  1   2   3   4 , Tiansu Wang  1   2   3   4 , Deniz Demircioglu …

Continue Reading Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting | DNA RNA and Cells

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting Details Category: DNA RNA and Cells Published on Tuesday, 18 April 2023 10:14 Hits: 247 — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML…

Continue Reading Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting | DNA RNA and Cells

Human Acute Myeloid Leukemia Reportedly Closely Mimicked for First Time by Transformative Models

Tisch Cancer Center scientists report that they have developed novel models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a “transformative resource” to study this cancer and eventually its drug response and drug resistance, according to research presented at the annual meeting of the American Association of Cancer…

Continue Reading Human Acute Myeloid Leukemia Reportedly Closely Mimicked for First Time by Transformative Models

Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. BEIJING–(BUSINESS WIRE)– Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. Oral Presentation: ICP-490 is…

Continue Reading Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

Caribou Biosciences, Inc. — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models — — CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for H2 2023 — BERKELEY, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a…

Continue Reading Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

Catamaran Bio Announces Preclinical Data from Allogeneic

Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential of TAILWIND® platform to create effective CAR-NK treatments for solid tumors BOSTON, April 11, 2023 (GLOBE NEWSWIRE) — Catamaran Bio, Inc., a biotechnology company developing off-the-shelf natural killer (NK) cell therapies to treat cancer, today…

Continue Reading Catamaran Bio Announces Preclinical Data from Allogeneic

NIH 1999 In Vivo Skin Targeted Gene Therapy By Electroporation

In vivo transfer of genetic information to cells of the skin may offer a useful therapy for skin-specific indications as well as systemic diseases such as hemophilia. The skin presents a large, easily accessible target that contains cells such as keratinocytes that can provide secretory capability to the circulatory system….

Continue Reading NIH 1999 In Vivo Skin Targeted Gene Therapy By Electroporation

Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms

Knockdown of LFPRLR reduces splenic B-cell subsets in SLE-prone mice To investigate whether the PRL-LFPRLR axis raises the risk of initiation of B-cell malignancies, we compared SLE-prone MRL-lpr mice treated with either control SMO or LFPRLR SMO. Among SLE-prone models, we chose MRL-lpr mice because they accumulate genetic lesions indicative…

Continue Reading Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms

RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation

RAGA regulates lung adenocarcinoma progression and macrophage phagocytosis We performed experiments to explore the role of RAGA in lung adenocarcinoma by in vitro cell culture and in vivo xenograft system. To this end, we generated RAGA knockdown A549 and H1299 cancer cells. In vitro cell proliferation assays showed that RAGA…

Continue Reading RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation

ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs

Summary of a Single-cell Guided Pipeline to Aid Repurposing of Drugs Using scRNA-seq data, ASGARD repurposes drugs for disease by fully accounting for the cellular heterogeneity of patients (Fig. 1, Formula 1 in “Methods” section). In ASGARD, every cell cluster in the diseased sample is paired to that in the normal…

Continue Reading ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs

circRNA ITGA7 restrains growth and enhances radiosensitivity by up-regulating SMAD4 in colorectal carcinoma

Abstract Circular RNAs have been reported to be widely involved in cancer cell tumorigenesis and drug resistance; here, the aim of this study was to investigate whether circRNA Integrin Subunit Alpha 7 (ITGA7) (circ_ITGA7) was associated with the tumor growth and radiosensitivity of colorectal cancer (CRC). We found that circ_ITGA7…

Continue Reading circRNA ITGA7 restrains growth and enhances radiosensitivity by up-regulating SMAD4 in colorectal carcinoma

A desirable transgenic strategy using GGTA1 endogenous promoter-mediated knock-in for xenotransplantation model

Lai, L. et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 295, 1089–1092. doi.org/10.1126/science.1068228 (2002). ADS  CAS  Article  PubMed  Google Scholar  Kuwaki, K. et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat. Med. 11, 29–31. doi.org/10.1038/nm1171 (2005). CAS  Article  PubMed  Google…

Continue Reading A desirable transgenic strategy using GGTA1 endogenous promoter-mediated knock-in for xenotransplantation model

Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer

. 2022 Apr 30;2022:7918067. doi: 10.1155/2022/7918067. eCollection 2022. Affiliations Expand Affiliations 1 Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu Province, China. 2 Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China. Free PMC article Item in Clipboard Meng…

Continue Reading Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer

N6-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance | Military Medical Research

Bioinformatics analyses revealed the involvement of m6A modification in cervical cancer progression To better understand whether and how m6A regulators contribute to cervical cancer progression, we first identified 9 m6A writers (WTAP, ZC3H13, METTL3, METTL14, METTL16, VIRMA, RBM15B, RBM15, and CBLL1), 15 m6A readers (FMR1, hnRNPA2B1, hnRNPC, YTHDF1/2/3, YTHDC1/2, LRPPRC,…

Continue Reading N6-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance | Military Medical Research

Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming

Background: Thymidine kinase 1 (TK1) is a cell cycle-dependent kinase that catalyzes the addition of a gamma-phosphate group to thymidine. The protumorigenic role of TK1 has been reported in various malignancies. However, the role of TK1 in skin cutaneous melanoma (SKCM) remains unclear. This study aimed to explore the molecular…

Continue Reading Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming

RNA polymerase II trapped on a molecular treadmill: Structural basis of persistent transcriptional arrest by a minor groove DNA binder

Significance Hairpin pyrrole-imidazole (Py-Im) polyamides can be programmed to bind a broad repertoire of DNA sequences. Py-Im small molecules can be used to target cancer-specific coding regions and block transcription elongation. This transcription blockage by Py-Im cannot be rescued by transcription elongation factors, such as TFIIS. The mechanism by which…

Continue Reading RNA polymerase II trapped on a molecular treadmill: Structural basis of persistent transcriptional arrest by a minor groove DNA binder

Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer b

Introduction Prostate cancer (PCa) is one of the most common genitourinary system malignant tumor in men worldwide. In Asian countries, many patients with PCa are often diagnosed at an advanced stage maybe mostly because of a large population base with relatively backward economic development and imperfect cancer screening system of…

Continue Reading Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer b

3 Questions on… Picking the Right Tumor Cell Models for Research

Technologies that have enabled this include tumoroids, and genome engineering techniques, such as CRISPR/Cas9. Patient-derived xenografts … Source link

Continue Reading 3 Questions on… Picking the Right Tumor Cell Models for Research